Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Cash (2016 - 2025)

Ligand Pharmaceuticals' Change in Cash history spans 16 years, with the latest figure at $35.6 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 309.2% year-over-year to $35.6 million; the TTM value through Dec 2025 reached $65.4 million, up 32.52%, while the annual FY2025 figure was $102.6 million, 107.93% up from the prior year.
  • Change in Cash for Q4 2025 was $35.6 million at Ligand Pharmaceuticals, up from -$24.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $45.5 million in Q3 2024 and bottomed at -$60.3 million in Q2 2023.
  • The 5-year median for Change in Cash is -$2.5 million (2021), against an average of $2.0 million.
  • The largest annual shift saw Change in Cash skyrocketed 1146.58% in 2022 before it crashed 637.71% in 2023.
  • A 5-year view of Change in Cash shows it stood at -$3.9 million in 2021, then surged by 1146.58% to $40.9 million in 2022, then plummeted by 92.43% to $3.1 million in 2023, then soared by 180.62% to $8.7 million in 2024, then skyrocketed by 309.2% to $35.6 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Change in Cash are $35.6 million (Q4 2025), -$24.3 million (Q1 2025), and $8.7 million (Q4 2024).